Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1779 of 6351
-
New pill for scarred lungs enters human testing
Disease control Recruiting nowThe purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
Phase 2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could a simple blood test predict clot risk in PCOS?
Knowledge-focused OngoingPolycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of childbearing age. PCOS can be individualized into several phenotypes, taking into account in particular the presence of hyperandrogenism, insulin resistance and BMI. Hyperandrogenism and insulin re…
Sponsor: Fondation Hôpital Saint-Joseph • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
AI and wearables join forces to uncover Dementia's hidden clues
Knowledge-focused OngoingInvestigate whether endogenous and exogenous risk factors, the presence of pathological amyloid aggregates and alpha-synuclein in the CSF, brain connectivity, and some clinical and biological indices such as vigilance, general motility, the sleep-wake cycle, genomic instability a…
Sponsor: IRCCS San Raffaele Roma • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Osteoporosis drug may also preserve muscle in the elderly
Disease control Recruiting nowOur goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
Phase 4 • Sponsor: Susan L. Greenspan • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail aims to outsmart resistant leukemia
Disease control OngoingInvestigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for rare ovarian cancer: Triple-Drug trial targets recurrent tumors
Disease control OngoingThis phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent). Darolutamide is in a class of medications called andr…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted pill alisertib under study
Disease control Recruiting nowPUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional…
Phase 2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Savoring the good may calm the Body's stress response
Symptom relief CompletedThis study aims to evaluate how savoring influences reward and threat processes and downstream inflammation. Savoring is designed to enhance positive affect, which may blunt stress responses and reduce downstream inflammation. The investigators aim to examine changes in the brain…
Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThe primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Phase 4 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New digital coaching aims to ease cancer pain and cut opioid risks
Symptom relief OngoingThis clinical trial tests a collaborative pain management intervention (ASCENT) for improving cancer pain in cancer survivors. Cancer pain is prevalent, under-treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain in…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New study aims to find best rectal cancer treatment for seniors
Disease control Recruiting nowThe SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal cancer.
Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cyt…
Phase 1 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a vaccine stop breast cancer before it starts? new trial launches
Prevention Recruiting nowWomen with biopsy-proven ductal carcinoma in situ (DCIS) will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor or selective estrogen receptor modulator (SERM) for about 12 weeks prior to surgery at 12 weeks. The second cohort w…
Phase 1 • Sponsor: Finn, Olivera, PhD • Aim: Prevention
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo aims to knock out stomach bug in phase 3 trial
Disease control CompletedThis study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for Helicobacter pylori
Phase 3 • Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for GVHD patients: experimental drug TDI01 enters human trials
Disease control Ongoing1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2. Phase II study stage: Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety
Phase 1/2 • Sponsor: Beijing Tide Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New PNH drug shows promise for Long-Term control
Disease control OngoingThis is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets or capsules until the end of treatment in this study.
Phase 2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surge…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Mind-Body physio program aims to tackle chronic pain and depression together
Symptom relief CompletedThis prospective longitudinal pre-post intervention study aims to evaluate the effects of an 8-week physiotherapy program combining face-to-face and asynchronous tele-rehabilitation sessions in individuals with chronic persistent pain and depressive disorder. The intervention is …
Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New texting system aims to boost cervical cancer screening in kenya
Disease control OngoingCervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent cervical cancer screening and retention through treat…
Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug targets tough cancer mutation in early trial
Disease control Recruiting nowPhase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Phase 1 • Sponsor: Quanta Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC